Galecto Inc

Damora Therapeutics, Inc. is a clinical-stage biotechnology company that develops small-molecule therapeutics for fibrosis, cancer, inflammation, and other related diseases. Its pipeline includes GB3226, a preclinical dual inhibitor of ENL-YEATS and FLT3, and GB1211, an oral galectin-3 inhibitor being developed for multiple oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark.